Latest news with #TAVI
Medscape
01-07-2025
- Health
- Medscape
Pacemaker Needs Rise After TAVI Procedures in Spain
TOPLINE: The incidence of implantation of a permanent pacemaker immediately after transcatheter aortic valve implantation (TAVI) increased significantly over a period of 6 years in Spain, and this rising trend remained independent of sex, age, comorbidities, or procedural volumes at the hospitals. METHODOLOGY: Researchers in Spain conducted a retrospective observational study using data from a national hospital discharge database to analyse the incidence of pacemaker implantation immediately after TAVI. They analysed 20,826 episodes of TAVI performed between 2017 and 2022 in patients older than 60 years without a prior pacemaker. The primary outcome was the implantation of a permanent pacemaker during the same hospitalisation as the TAVI procedure. TAKEAWAY: Overall, 16.8% of patients required the implantation of a pacemaker, with the yearly incidence of implantation increased from 15.2% to 18.2% from 2017 to 2022 (P for trend < .001). The rising trend in pacemaker implantation was independent of sex, age, or burden of comorbidities and was not significantly influenced by the annual volume of TAVI performed at the hospitals. IN PRACTICE: "[The study] findings are clinically relevant and should be considered when selecting patients and optimising the procedure to reduce the need for post-TAVI pacemaker implantation," the authors wrote. SOURCE: This study was led by Manuel Carnero-Alcázar, MD, PhD, Hospital Clínico San Carlos, Madrid, Spain. It was published online on June 18, 2025, in Open Heart. LIMITATIONS: The dataset used in this study lacked information on procedural characteristics such as depth of implantation and type of valve. The retrospective and observational study design prevented the investigators from determining whether the analysed variables directly increased the pacemaker risk. Pacemaker implantation was captured only during the initial admission to the hospital. DISCLOSURES: This study did not receive any specific funding. The authors declared having no conflicts of interest. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Yahoo
27-06-2025
- Health
- Yahoo
New treatment for heart valve disease in the East
Patients received a new treatment for heart valve disease, which did not require riskier open-heart surgery or travel to London. Five people from Cambridgeshire, Essex, Hertfordshire, Peterborough and Suffolk had the minimally invasive procedure at the Royal Papworth Hospital in Cambridge. It saw them treated for aortic valve regurgitation, which is when blood flows the wrong way through the heart, causing breathlessness, chest pain, fatigue and a fluid build-up. Mary Baker, 79, said she received a transcatheter aortic valve implantation (TAVI) on a Monday and was home by teatime on the Wednesday. Ms Baker from Bishop's Stortford in Hertfordshire was treated in May 2025 and said she was "feeling a thousand percent better". It was deemed too risky to fix her leaky heart valve with open heart surgery, so she had a TAVI fitted at the Cambridge hospital. "I used to play golf and go to the gym two to three times a week, but my condition built up gradually, and I was feeling really poorly because my valve was leaking quite badly," she said. "I was so short of breath all the time – I could barely walk a few yards without stopping, and even talking to people was hard." Since her treatment, she had started driving again and planned to get back to playing golf and going to the gym. Royal Papworth Hospital NHS Foundation Trust was the only hospital in the East of England, and one of a few in the UK, using the Trilogy valve technology. Another patient, a 76-year-old woman from Leigh-on-Sea in Essex, also underwent the procedure in May and has noticed a big improvement in her breathing. She explained: "Beforehand, I couldn't walk very far, and I couldn't do quite a few things around the house because I was getting out of breath so quickly. "Having the Trilogy TAVI valve has really improved my quality of life. I've just had a wander around the supermarket and bought some groceries, and I came home and unpacked everything from the car." Dr Charis Costopoulos said: "These patients now can have definitive treatment here. "Previously, people who were deemed inoperable would bounce in and out of hospital with little quality of life between admissions. "It also means that high-risk patients who would otherwise have surgical aortic valve replacement as their only option can now be treated minimally invasively, resulting in reduced hospital length of stay and much quicker recovery." Follow East of England news on X, Instagram and Facebook: BBC Beds, Herts & Bucks, BBC Cambridgeshire, BBC Essex, BBC Norfolk, BBC Northamptonshire or BBC Suffolk. Runner breaks world record after heart surgery AI study collects thousands of heart recordings Woman, 80, undergoes rare three-valve heart op Royal Papworth Hospital NHS Foundation Trust
BBC News
27-06-2025
- Health
- BBC News
East of England heart valve patients undergo less invasive op
Patients received a new treatment for heart valve disease, which did not require riskier open-heart surgery or travel to people from Cambridgeshire, Essex, Hertfordshire, Peterborough and Suffolk had the minimally invasive procedure at the Royal Papworth Hospital in saw them treated for aortic valve regurgitation, which is when blood flows the wrong way through the heart, causing breathlessness, chest pain, fatigue and a fluid Baker, 79, said she received a transcatheter aortic valve implantation (TAVI) on a Monday and was home by teatime on the Wednesday. Ms Baker from Bishop's Stortford in Hertfordshire was treated in May 2025 and said she was "feeling a thousand percent better".It was deemed too risky to fix her leaky heart valve with open heart surgery, so she had a TAVI fitted at the Cambridge hospital."I used to play golf and go to the gym two to three times a week, but my condition built up gradually, and I was feeling really poorly because my valve was leaking quite badly," she said."I was so short of breath all the time – I could barely walk a few yards without stopping, and even talking to people was hard."Since her treatment, she had started driving again and planned to get back to playing golf and going to the Papworth Hospital NHS Foundation Trust was the only hospital in the East of England, and one of a few in the UK, using the Trilogy valve technology. Another patient, a 76-year-old woman from Leigh-on-Sea in Essex, also underwent the procedure in May and has noticed a big improvement in her explained: "Beforehand, I couldn't walk very far, and I couldn't do quite a few things around the house because I was getting out of breath so quickly."Having the Trilogy TAVI valve has really improved my quality of life. I've just had a wander around the supermarket and bought some groceries, and I came home and unpacked everything from the car."Dr Charis Costopoulos said: "These patients now can have definitive treatment here. "Previously, people who were deemed inoperable would bounce in and out of hospital with little quality of life between admissions."It also means that high-risk patients who would otherwise have surgical aortic valve replacement as their only option can now be treated minimally invasively, resulting in reduced hospital length of stay and much quicker recovery." Follow East of England news on X, Instagram and Facebook: BBC Beds, Herts & Bucks, BBC Cambridgeshire, BBC Essex, BBC Norfolk, BBC Northamptonshire or BBC Suffolk.
India Today
24-06-2025
- Health
- India Today
Meril Launches MyClip, India's First Transcatheter-Edge-to-Edge Repair (TEER) System for Treatment of Severe Mitral Regurgitation
Meril Life Sciences, a leading global med-tech company, marked a significant milestone with the launch of MyClip, India's first Transcatheter Edge-To-Edge Repair (TEER) system, on June 14. The landmark Structural Heart Innovation event, held at Meril Academy, Vapi (Gujarat) from June 13–15, brought together over 150 Indian interventional cardiologists along with cardiac imaging expert and international stalwarts, including Prof. Ottavio Alfieri ('Father of mitral valve repair'), Prof. Francesco Maisano, and Prof. Agricola, joining global pioneers in edge-to-edge mitral valve is currently the world's leading TAVI group following the success of Myval THV and first Indian company to introduce a TEER system, placing the country firmly on the map as an innovator in transcatheter heart valve therapies (with both replacement and repair technology platforms). MyClip introduction demonstrates India's growing capabilities in structural heart solutions and reflects Meril's commitment to accessible cutting-edge cardiac TEER System is designed for patients suffering from severe Mitral Regurgitation (MR) who are at high surgical risk due to pre-existing issues like hypertension, diabetes, obesity, advanced age, physical frailty, enlarged or weak heart, and patients with kidney, lung and liver problems. MR, particularly if untreated, has a devastating mortality rate—over 50% of patients may not survive without timely intervention, and 1-year mortality can be as high as 57%.The MyClip TEER System enables precise closure of the mitral valve flaps, effectively preventing the backward flow of purified blood into the lungs. The procedure is minimally invasive, & takes approximately one hour, and allows patients to return home within 3–5 days. After discharge, patients can resume daily activities like walking and non-strenuous work within a short period post the to the landmark COAPT Study published in the New England Journal of Medicine (NEJM), patients receiving device-based therapy for mitral regurgitation experienced significantly better outcomes compared to those receiving standard medical treatment. Within 24 months, the hospitalization rate for heart failure was reduced to 35.8% per patient-year in the device group, compared to 67.9% in the control group. Additionally, mortality within the same period was notably lower in the device group, at 29.1%, compared to 46.1% in the control approximately 150 TEER (Transcatheter Edge-to-Edge Repair) procedures are performed annually in India, with the majority of patients falling in the younger age group (30 – 60). These statistics bring to light a pressing need for early and effective intervention in younger launch of MyClip TEER System marks a transformative moment for structural heart therapy in India. Transcatheter Edge-to-Edge Repair (TEER) therapy has shown significant success over traditional Guideline Directed Medical Therapy (GDMT). MyClip represents a major step forward in India's cardiovascular treatment landscape. In his inaugural speech, Sanjeev Bhatt, Senior Vice President of Corporate Strategy at Meril Life Sciences, said, 'In India, around 1.5 million people are known to have severe mitral regurgitation. Of these at least 1.2 million are post myocardial infarction (MI or a heart attack) or due to heart failure. Introduction of the MyClip TEER system marks a pivotal shift and we're witnessing early adoption. Meril's efforts in training cardiologists and building TEE-based imaging expertise are crucial steps in scaling this life-saving therapy across the country."'With MyClip, Meril is reshaping the country's role in global medtech. This homegrown innovation is a testament to what Indian science, engineering, and clinical collaboration can achieve together. Meril's nationwide public awareness campaign #TreatmentZarooriHai is in full swing, with brand ambassador MS Dhoni, to educate patients and families about the life-saving value of timely intervention in mitral valve regurgitation,' Mr. Bhatt two-day Structural Heart Innovation scientific program featured case demonstrations, interactive hands-on workshops, and the presentations leading Interventional Cardiologists and Echocardiologists. The event concluded with a call to build a sustainable M-TEER ecosystem in India, focused on accessibility, clinical excellence, and continuous The material and information contained are for advertorial purposes only. India Today holds no responsibility for the content written on the website as a basis for making any business, legal, or any other decision. Any reliance placed on such material is at your own risk.- Ends advertisement
News18
11-06-2025
- Health
- News18
Beyond Blockages: Structural Heart Disease and the Rise of Minimally Invasive Solutions
Last Updated: A common example of structural heart disease is aortic valve stenosis, especially in patients over 60 years old. Heart disease is often associated with blocked arteries and heart attacks, but there's another lesser-known category of heart conditions that demands attention: structural heart disease. While coronary artery disease is defined by the narrowing or blockage of arteries that nourish the heart muscle, structural heart disease refers to abnormalities or defects in the heart's valves, walls, muscles, or chambers. These can be congenital—present from birth—or acquired over time due to aging, infections such as rheumatic fever, or degenerative changes. A common example of structural heart disease is aortic valve stenosis, especially in patients over 60 years old. This occurs when calcium deposits restrict and stiffen the aortic valve, making it harder for the heart to pump blood efficiently. Another congenital condition is the bicuspid aortic valve, where the valve has only two cusps instead of the usual three, leading to accelerated wear and valve failure, often in younger adults. Dr. Yugal Mishra, Chief of Clinical Services, Chairman of the Manipal Institute of Cardiac Sciences, and Chief Cardiovascular Surgeon at Manipal Hospital, Dwarka, New Delhi, shares everything you need to know: New symptoms of structural heart disease can include difficulty breathing, fatigue during everyday activities, chest discomfort, irregular heartbeats, or swelling in the limbs or abdomen. These may signal that the heart's valves or chambers are not functioning properly and require immediate medical attention. Surgical options such as valve repair or replacement remain effective, particularly in younger patients or those with minimal comorbidities. However, less invasive options have revolutionized care for older patients or those with additional kidney or lung complications. One such procedure is TAVR (Transcatheter Aortic Valve Replacement), also known as TAVI. In this approach, a prosthetic valve is inserted via catheter through an artery, avoiding the need for open-heart surgery. This minimally invasive method is particularly beneficial for patients with severely compromised health, offering restored heart function, faster recovery, and improved quality of life. Advanced therapies like TAVR offer renewed hope for living a healthier, more fulfilling life. If you or a loved one is experiencing recurring cardiac symptoms, it is advisable to consult a cardiologist. Early detection and timely intervention can make all the difference. As highlighted by the World Health Organization, cardiovascular disease (CVD)—including heart attacks and strokes—remains the leading cause of death worldwide. Alarmingly, many of these deaths are premature, especially among individuals under 70. Aortic stenosis (AS) is a prime example of a condition that can progress silently until it becomes critical. To further improve outcomes, the SMART trial evaluated various valve types used in TAVR procedures, enhancing treatment protocols, safety, and long-term success rates. For India to meet the growing burden of heart disease, a multi-faceted healthcare approach—combining early diagnostics and innovative treatments like TAVI—is essential to transform cardiac care and improve patient outcomes. News lifestyle » health-and-fitness Beyond Blockages: Structural Heart Disease and the Rise of Minimally Invasive Solutions
